Cargando…
Multicentre single-arm phase II trial evaluating the safety and effiCacy of Panitumumab and iRinOtecan in NeoRAS Wild-type mEtaStatic colorectal cancer patientS (C-PROWESS trial): study protocol
INTRODUCTION: A new concept of ‘NeoRAS wild-type (WT)’, which means conversion of RAS status from RAS mutant to RAS WT after treatment, has been reported. Previous observational and proof-of-concept studies have demonstrated the efficacy of epidermal growth factor receptor inhibitors in patients wit...
Autores principales: | Osumi, Hiroki, Ishizuka, Naoki, Takashima, Atsuo, Kumekawa, Yosuke, Nakano, Daisuke, Shiozawa, Manabu, Denda, Tadamichi, Sawada, Ryoichi, Ouchi, Kota, Wakatsuki, Takeru, Narikazu, Boku, Kato, Ken, Yamaguchi, Kensei, Shinozaki, Eiji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438189/ https://www.ncbi.nlm.nih.gov/pubmed/36581973 http://dx.doi.org/10.1136/bmjopen-2022-063071 |
Ejemplares similares
-
A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2023) -
Effi Briest /
por: Fontane, Theodor, 1819-1898
Publicado: (1983) -
Effi Briest /
por: Fontane, Theodor, 1819-1898
Publicado: (1981) -
Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐WJOG 6210G
por: Shitara, Kohei, et al.
Publicado: (2016) -
Severe sepsis: are PROWESS and PROWESS-SHOCK trials comparable? A clinical and statistical heterogeneity analysis
por: Kalil, Andre C, et al.
Publicado: (2013)